Clinical characteristics of bone disease in multiple myeloma and clinical significance of monitoring bone metabolic markers

被引：1
|
作者：
褚彬 [1 ]
机构：
[1] Dept Hematol, Beijing Jishuitan Hosp
来源：
ChinaMedicalAbstracts(InternalMedicine) | 2016年 / 33卷 / 03期
关键词：
bone; CTX; PINP;
D O I：
暂无
中图分类号：
R733.3 [骨髓肿瘤];
学科分类号：
摘要：
Objective To observe the clinical characteristics of bone disease in patients with multiple myeloma(MM)and the clinical significance of monitoring bone metabolic markers.Methods The data of 178 MM case newly diagnosed in Beijing Ji Shui Tan Hospital from January 2009to June 2014 were reviewed to analyze the types and classification of bone disease and to observe the clinical char-
引用
收藏
页码：184 / 185
页数：2
相关论文
共 50 条
  • [11] Treatment of multiple myeloma bone disease: experimental and clinical data
    Papamerkouriou, Yvonne Mary
    Kenanidis, Eustathios
    Gamie, Zakareya
    Papavasiliou, Kyriakos
    Kostakos, Thomas
    Potoupnis, Michael
    Sarris, Ioannis
    Tsiridis, Eleftherios
    Kyrkos, John
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (02) : 213 - 230
  • [12] Significance of bone marrow fibrosis in monitoring multiple myeloma
    Babarovic, E.
    Valkovic, T.
    Stifter, S.
    Duletic-Nacinovic, A.
    Petranovic, D.
    Seili-Bekafigo, I.
    Lucin, K.
    Jonjic, N.
    VIRCHOWS ARCHIV, 2010, 457 (02) : 191 - 192
  • [13] BIOCHEMICAL MARKERS OF BONE TURNOVER FOR THE CLINICAL-ASSESSMENT OF METABOLIC BONE-DISEASE
    DELMAS, PD
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1990, 19 (01) : 1 - 18
  • [14] Markers of bone turnover Overview and clinical significance
    Schwetz, V.
    Obermayer-Pietsch, B.
    OSTEOLOGIE, 2015, 24 (04) : 215 - 218
  • [15] Bone markers in multiple myeloma
    Heider, Ulrike
    Fleissner, Claudia
    Zavrski, Ivana
    Kaiser, Martin
    Hecht, Monica
    Jakob, Christian
    Sezer, Orhan
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (11) : 1544 - 1553
  • [16] Bone marrow angiogenesis and progression in multiple myeloma: Clinical significance and therapeutic approach
    Eleutherakis-Papaiakovou, V
    Karali, M
    Kokkonouzis, I
    Tiliakos, I
    Dimopoulos, MA
    LEUKEMIA & LYMPHOMA, 2003, 44 (06) : 937 - 948
  • [17] Modern markers for evaluating bone disease in multiple myeloma
    Pop, Vlad
    Parvu, Andrada
    Craciun, Alexandra
    Farcas, Anca Daniela
    Tomoaia, Gheorghe
    Bojan, Anca
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (05)
  • [18] Risk Factors and Clinical Characteristics of Metabolic Bone Disease of Prematurity
    Mutlu, Mehmet
    Akturk-Acar, Filiz
    Kader, Sebnem
    Aslan, Yakup
    Karaguzel, Gulay
    AMERICAN JOURNAL OF PERINATOLOGY, 2023, 40 (05) : 519 - 524
  • [19] BONE BIOMARKERS ARE USEFUL IN MONITORING MYELOMA BONE DISEASE AND AS EARLY PREDICTOR FOR RELAPSE DISEASE IN MULTIPLE MYELOMA
    Ting, K.
    Hameed, A.
    Brady, J.
    Carke, C.
    Justine, M.
    Dowling, P.
    Clynes, M.
    O'Gorman, P.
    HAEMATOLOGICA, 2013, 98 : 334 - 335
  • [20] RESPONSE ASSESSMENT IN MULTIPLE MYELOMA: CLINICAL SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING
    Paiva, Bruno
    Vidriales, Maria-Belen
    Montalban, Maria-Angeles
    Blade, Joan
    Lahuerta, Juan-Jose
    Orfao, Alberto
    San Miguel, Jesus F.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2011, 80B (06) : 390 - 390
12345